e-Drug3D

2017

TRILACICLIB

INN
TRILACICLIB

cas 1374743-00-6

CLASS

ANTINEOPLASTIC
CDK4 AND CDK6 KINASE INHIBITOR
TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION

ROUTE (list)

INTRAVENOUS

ATC code

V03AF12

PK parameters

VD 1130 LITER
Cl 158 LITER / HOUR
t1/2 14 HOUR

Target

TARGET CDK4
CDK6

Cyclin-dependent kinase 6 UNIPROT Q00534 CDK6

Cyclin-dependent kinase 4 UNIPROT P11802 CDK4

Download SDF file

Spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one, 7',8'-dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]-

Formula:
C24H30N8O

Calculated chemical properties:

MW 446.56
NB_atoms 33
XLogP 2.72
PSA 80.029
NB_HD 2
NB_HA 9
fsp3 0.50
Lipinski(0=no;1=yes) 1

FDA
NDA 214200 (label) INN (TRILACICLIB DIHYDROCHLORIDE) COSELA (PHARMACOSMOS) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY